bi-specific Peptimetics (Antyra)

N/A

Report date: 2026/04/29 16:42:16
NME

Base Information

Drug Namebi-specific Peptimetics (Antyra)
Drug Alias NameB-Peptimetics (Antyra)IGF-1/EGF receptor antagonists (Antyra)
ClassificationSmall molecules > Peptidomimetic
Mechanisms of ActionInsulin-like growth factor I receptor antagonistsEpidermal growth factor receptor erbB1 antagonists
TargetsInsulin-like growth factor I receptorEpidermal growth factor receptor erbB1
Therapy Area/IndicationsAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAntyra Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAntyra Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A